CA3176391A1 - Anti-cd3 antibodies and uses thereof - Google Patents

Anti-cd3 antibodies and uses thereof Download PDF

Info

Publication number
CA3176391A1
CA3176391A1 CA3176391A CA3176391A CA3176391A1 CA 3176391 A1 CA3176391 A1 CA 3176391A1 CA 3176391 A CA3176391 A CA 3176391A CA 3176391 A CA3176391 A CA 3176391A CA 3176391 A1 CA3176391 A1 CA 3176391A1
Authority
CA
Canada
Prior art keywords
seq
antibody
immunoglobulin
binding fragment
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176391A
Other languages
English (en)
French (fr)
Inventor
Nai-Kong V. Cheung
Sayed Shahabuddin HOSEINI
Hong Xu
Brian SANTICH
Mahiuddin Ahmed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA3176391A1 publication Critical patent/CA3176391A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
CA3176391A 2020-04-24 2021-04-23 Anti-cd3 antibodies and uses thereof Pending CA3176391A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063015149P 2020-04-24 2020-04-24
US63/015,149 2020-04-24
PCT/US2021/028798 WO2021216972A1 (en) 2020-04-24 2021-04-23 Anti-cd3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3176391A1 true CA3176391A1 (en) 2021-10-28

Family

ID=78270196

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176391A Pending CA3176391A1 (en) 2020-04-24 2021-04-23 Anti-cd3 antibodies and uses thereof

Country Status (6)

Country Link
US (1) US20230212289A1 (https=)
EP (1) EP4139347A4 (https=)
JP (1) JP7791836B2 (https=)
CN (1) CN115803340A (https=)
CA (1) CA3176391A1 (https=)
WO (1) WO2021216972A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023205733A1 (en) * 2022-04-21 2023-10-26 Academia Sinica Genetically engineered innate lymphoid cells for enhancing lifespan and/or treating cancers
US20260042860A1 (en) * 2022-08-04 2026-02-12 Memorial Sloan-Kettering Cancer Center Anti-cd24 antibodies and uses thereof
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
WO2024199454A1 (en) * 2023-03-29 2024-10-03 Nanjing GenScript Biotech Co., Ltd. Antibodies and variants thereof against human cluster of differentiation 3 protein
CN116574182B (zh) * 2023-06-09 2024-02-06 上海交通大学医学院附属第九人民医院 一种抗人Ki-67抗体及其制备方法和用途
CN121293363B (zh) * 2025-12-09 2026-04-21 上海玄言生物科技有限公司 一种靶向cd14和cd3的双功能t细胞衔接器及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720565A2 (pt) * 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso
CN102796199A (zh) * 2011-05-26 2012-11-28 中国医学科学院血液病医院 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
CN103173478B (zh) * 2013-03-04 2015-09-09 西北大学 一种携带ptd的抗人cd3单链抗体的制备方法
CN103467605B (zh) * 2013-09-05 2015-02-04 武汉友芝友生物制药有限公司 一种cd3抗原及其制备方法和用途
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
RU2020122439A (ru) * 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
US20180371088A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
MX2020009774A (es) * 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
EP3802595A1 (en) * 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
WO2020062155A1 (en) 2018-09-29 2020-04-02 Mab-Legend Biotech Co., Ltd. Dual targeting antigen binding molecule
CN110964114B (zh) 2018-09-29 2023-07-04 上海博槿生物科技有限公司 一种双靶点抗原结合分子

Also Published As

Publication number Publication date
JP2023523584A (ja) 2023-06-06
EP4139347A4 (en) 2024-06-05
CN115803340A (zh) 2023-03-14
JP7791836B2 (ja) 2025-12-24
WO2021216972A1 (en) 2021-10-28
EP4139347A1 (en) 2023-03-01
US20230212289A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP7791836B2 (ja) 抗ｃｄ３抗体及びその使用
US12441793B2 (en) CD33 antibodies and methods of using the same to treat cancer
JP7730295B2 (ja) Ｃｄ１９抗体およびこれを使用する方法
JP7805287B2 (ja) 抗ｓｔｅａｐ１抗体およびその使用
US12509515B2 (en) CD22 antibodies and methods of using the same
US20220251192A1 (en) Anti-cd33 antibodies for treating cancer
US20260015435A1 (en) Anti-polysialic acid antibodies and uses thereof
US20220242967A1 (en) Anti-glypican-3 antibodies and uses thereof
US20240026037A1 (en) Anti-gpa33 multi-specific antibodies and uses thereof
US20230374150A1 (en) Anti-psma antibodies and uses thereof
US12612456B2 (en) CD19 antibodies and methods of using the same
AU2024344464A1 (en) Gpa33 antibody compositions and uses thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250422

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250423

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250619

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250619

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250619

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250709

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260323

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260323